Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Marta Garofoli"'
Autor:
Paolo Verdecchia, Fabio Angeli, Giovanni Mazzotta, Claudia Bartolini, Marta Garofoli, Adolfo Aita, Cristina Poltronieri, Maria Gabriella Pinzagli, Francesca Valecchi, Stefania Martone, Elisa Ramundo, Dario Turturiello, Gianpaolo Reboldi
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 6, Iss 6 (2017)
BackgroundThe different geometric patterns of the left ventricle may or may not coexist with chamber dilatation. The prognostic impact of such a combination is unclear. Methods and ResultsWe studied a cohort of 2635 initially untreated patients with
Externí odkaz:
https://doaj.org/article/cbcc17ebfd7e4680a12c82e4ed629fb7
Autor:
Fabio Angeli, Gianpaolo Reboldi, Cristina Poltronieri, Giovanni Mazzotta, Marta Garofoli, Elisa Ramundo, Alessandra Biadetti, Paolo Verdecchia
Publikováno v:
Italian Journal of Medicine, Vol 6, Iss 4 (2012)
Introduction The aim of this review was to summarize the current state of evidence regarding the optimal blood pressure goals in patients with high vascular risk. In particular, this review critically addresses the issue of the “J-curve” paradox
Externí odkaz:
https://doaj.org/article/eed535559b144d4bbbf42d9a7b0520d6
Autor:
Stefania Martone, Cristina Poltronieri, Elisa Ramundo, Dario Turturiello, Paolo Verdecchia, Fabio Angeli, Marta Garofoli, Adolfo Aita, Giovanni Mazzotta, Gianpaolo Reboldi, Maria Gabriella Pinzagli, Francesca Valecchi, Claudia Bartolini
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background The different geometric patterns of the left ventricle may or may not coexist with chamber dilatation. The prognostic impact of such a combination is unclear. Methods and Results We studied a cohort of 2635 initially untreated patients wit
Autor:
Paolo Verdecchia, Gianpaolo Reboldi, Fabio Angeli, Ludovico Lazzari, Marta Garofoli, Claudia Bartolini, Martina Sordi, Cristina Poltronieri
Publikováno v:
Therapeutic Advances in Cardiovascular Disease. 9:412-424
Hyperglycemia is a frequent condition in patients with acute coronary syndromes (ACS). Hyperglycemia during ACS is caused by an inflammatory and adrenergic response to ischemic stress, when catecholamines are released and glycogenolysis induced. Alth
Publikováno v:
Hypertension. 63:37-40
Blood pressure (BP) is poorly controlled in the population, a phenomenon with adverse prognostic impact.1 However, a more aggressive approach toward BP lowering has been tempered over the last 2 to 3 decades by some reports suggesting a paradoxical i
Autor:
Paolo, Verdecchia, Fabio, Angeli, Adolfo, Aita, Claudia, Bartolini, Marta, Garofoli, Gianpaolo, Reboldi
Publikováno v:
Giornale italiano di cardiologia (2006). 17(5)
The SPRINT study tested the hypothesis that hypertensive patients randomized to a more intensive treatment, aimed at lowering systolic blood pressure (BP) below 120 mmHg have a lower incidence of major cardiovascular events when compared to patients
Autor:
Paolo Verdecchia, Gianpaolo Reboldi, Giovanni Mazzotta, Cristina Poltronieri, Fabio Angeli, Elisa Ramundo, Marta Garofoli, Giuseppe Ambrosio
Publikováno v:
Current Cardiology Reports. 14:601-610
Atrial fibrillation (AF) confers an increased risk of mortality in patients hospitalized for acute myocardial infarction (AMI). However, it is unclear whether new-onset and preexisting AF portend a different risk. We extracted data from studies that
Autor:
Elisa Ramundo, Gianpaolo Reboldi, Paolo Verdecchia, Giorgio Gentile, Fabio Angeli, Marta Garofoli, Giuseppe Ambrosio, Giovanni Mazzotta
Publikováno v:
Hypertension. 60:34-42
We investigated the relationship between the day-night blood pressure (BP) dip and the early morning BP surge in an cohort of 3012 initially untreated subjects with essential hypertension. The day-night reduction in systolic BP showed a direct associ
Safety and Efficacy of Aliskiren in the Treatment of Hypertension and Associated Clinical Conditions
Autor:
Alessandra Biadetti, Cristina Poltronieri, Gianpaolo Reboldi, Fabio Angeli, Marta Garofoli, Giovanni Mazzotta, Paolo Verdecchia, Elisa Ramundo
Publikováno v:
Scopus-Elsevier
Aliskiren is the first known representative of a new class of non-peptide orally active renin inhibitors that blocks the renin-angiotensin-aldosterone-system (RAAS) at its rate-limiting step. It induces a net reduction in plasma renin activity (PRA),
Autor:
Paolo Verdecchia, Giorgio Gentile, Gianpaolo Reboldi, Fabio Angeli, Marta Garofoli, Paola Martire, Giovanni Mazzotta
Publikováno v:
Therapeutic Advances in Cardiovascular Disease. 4:193-200
Aliskiren is an orally active direct renin inhibitor which inhibits the synthesis of angiotensin I by linking to active renin on a deep cleft of its molecular structure, the site of hydrolysis of the Leu10-Val11 bond of angiotensinogen. At variance w